Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher Scientific; Agilent; Shuwen Biotech; and More

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced this week that it has completed its $4.2 billion acquisition of electron microscopy company FEI. Thermo Fisher paid $107.50 per share in cash. FEI will become part of Thermo Fisher's analytical instruments business unit.

Agilent Technologies said this week that its board has approved a quarterly dividend of $.12 per share of common stock, to be paid on Oct. 26, to all shareholders of record as of Oct. 4.

Chinese diagnostics company Shuwen Biotech announced this week that it has received accreditation from the College of American Pathologists for its China-based clinical lab, Shuwen Guanz Diagnostic Lab.

Quantapore reported this week that it has closed a Series C financing round, led by venture capital fund China BioPharma Capital I. Details of the financing were not disclosed. Quantapore is developing a single-molecule sequencing technology that uses an optical readout.

The American Society of Human Genetics and the Mayo Clinic Center for Individualized Medicine announced this week that they have agreed to collaborate on educating health professionals on the effective use of genomics in medicine. The first joint ASHG-CIM educational program will be targeted toward Ob/Gyns and related health professionals, and will address prenatal cell-free DNA screening in pregnant women.

MDxHealth reported this week that its preliminary unaudited revenues are expected to significantly exceed the upper end of its previously reported full year guidance. The company is expecting 2016 revenues to grow 60 percent over 2015 revenues. Previous guidance had called for a revenue increase of 30 percent to 50 percent. MDxHealth attributed the additional growth to accelerated adoption of the its ConfirmMDx test for prostate cancer, which was included in the US National Comprehensive Cancer Network Clinical Guidelines in the first quarter.

Sygnis said this week that US business unit Navicyte Scientific has signed a deal with the UK's European Collection of Authenticated Cell Cultures to license and distribute the Caco-2 cell line to commercial companies. Caco-2 cells were developed by the Memorial Sloan Kettering Cancer Center, and the cell line is the recognized gold standard for absorption assays.

Roka Bioscience announced this week that it has completed a previously announced private placement of approximately 22,500 shares of its Series A preferred stock, and five-year warrants to purchase approximately 32.1 million shares of common stock. After deducting fees and expenses, net proceeds to the company from the private placement are expected to be approximately $21.3 million. Roka intends to use the proceeds for general corporate purposes.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.